Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation

Journal of Molecular and Cellular Cardiology

Volumn 46, Issue 5, 2009, Pages 682-694

  Kasza, Zsolt ^a   Fetalvero, Kristina M ^a   Ding, Min ^a   Wagner, Robert J ^a   Acs, Klara ^a   Guzman, Anthony K ^a   Douville, Karen L ^a   Powell, Richard J ^a   Hwa, John ^a   Martin, Kathleen A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Akt 1; COX 2; Differentiation; Human vascular smooth muscle cells; Iloprost; Prostacyclin receptor; Signaling

Indexed keywords

AKT1 PROTEIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; ICOSANOID; ILOPROST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTERY ENDOTHELIUM; ARTERY MEDIA; ARTICLE; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME INDUCTION; FEEDBACK SYSTEM; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MUSCLE CONTRACTILITY; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TUNICA MEDIA; UPREGULATION; VASCULAR ENDOTHELIUM;

AORTA; CELL DIFFERENTIATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE 2; ENZYME INDUCTION; HUMANS; ILOPROST; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PARACRINE COMMUNICATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION; UP-REGULATION;

MUS;

EID: 63349100855     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.01.006     Document Type: Article

References (34)

1. Arehart E., Gleim S., Kasza Z., Fetalvero K.M., Martin K.A., and Hwa J. Prostacyclin, atherothrombosis, and cardiovascular disease. Curr Med Chem 14 (2007) 2161-2169
2. Fetalvero K.M., Shyu M., Nomikos A.P., Chiu Y.F., Wagner R.J., Powell R.J., et al. The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol 290 (2006) H1337-H1346
3. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., and FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U SA 96 (1999) 272-277
4. Topper J.N., Cai J., Falb D., and Gimbrone Jr. M.A. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 93 (1996) 10417-10422
5. Fitzgerald G.A. Coxibs and cardiovascular disease. N Engl J Med 351 (2004) 1709-1711
6. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 (1997) 678-682
7. Cheng Y., Austin S.C., Rocca B., Koller B.H., Coffman T.M., Grosser T., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 5567 (2002) 539-541
8. Egan K.M., Lawson J.A., Fries S., Koller B., Rader D.J., Smyth E.M., et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306 (2004) 1954-1957
9. Stitham J., Stojanovic A., Merenick B.L., O'Hara K.A., and Hwa J. The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. J Biol Chem 278 (2003) 4250-4257
10. Stitham J., Stojanovic A., Ross L.A., Blount Jr. A.C., and Hwa J. Clusters of transmembrane residues are critical for human prostacyclin receptor activation. Biochemistry 43 (2004) 8974-8986
11. Stitham J., Martin K.A., and Hwa J. The critical role of transmembrane prolines in human prostacyclin receptor activation. Mol Pharmacol 61 (2002) 1202-1210
12. Stitham J., Gleim S.R., Douville K., Arehart E., and Hwa J. Versatility and differential roles of cysteine residues in human prostacyclin receptor structure and function. J Biol Chem 281 (2006) 37227-37236
13. Stitham J., Stojanovic A., and Hwa J. Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J Biol Chem 277 (2002) 15439-15444
14. Martin K.A., Rzucidlo E.M., Merenick B.L., Fingar D.C., Brown D.J., Wagner R.J., et al. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 286 3 (2004) C507-C517
15. Martin K.A., Merenick B.L., Ding M., Fetalvero K.M., Rzucidlo E.M., Kozul C.D., et al. Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling. J Biol Chem 282 (2007) 36112-36120
16. Debey S., Meyer-Kirchrath J., and Schror K. Regulation of cyclooxygenase-2 expression by iloprost in human vascular smooth muscle cells. Role of transcription factors CREB and ICER. Biochem Pharmacol 65 (2003) 979-988
17. Manning B.D., and Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 129 7 (2007) 1261-1274
18. Beaulieu J.M., Gainetdinov R.R., and Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 28 (2007) 166-172
19. Ballou L.M., Lin H.Y., Fan G., Jiang Y.P., and Lin R.Z. Activated G alpha q inhibits p110 alpha phosphatidylinositol 3-kinase and Akt. J Biol Chem 278 (2003) 23472-23479
20. Liu F., Yang P., Baez M., and Ni B. Neurotensin negatively modulates Akt activity in neurotensin receptor-1-transfected AV12 cells. J Cell Biochem 92 (2004) 603-611
21. Mitchell D., Rodgers K., Hanly J., McMahon B., Brady H.R., Martin F., et al. Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells. Am J Pathol 164 (2004) 937-946
22. Rahman A., True A.L., Anwar K.N., Ye R.D., Voyno-Yasenetskaya T.A., and Malik A.B. Galpha(q) and Gbetagamma regulate PAR-1 signaling of thrombin-induced NF-kappaB activation and ICAM-1 transcription in endothelial cells. Circ Res 91 (2002) 398-405
23. Anger T., Klintworth N., Stumpf C., Daniel W.G., Mende U., and Garlichs C.D. RGS protein specificity towards Gq- and Gi/o-mediated ERK 1/2 and Akt activation, in vitro. J Biochem Mol Biol 40 (2007) 899-910
24. Miggin S.M., and Kinsella B.T. Investigation of the mechanisms of G protein: effector coupling by the human and mouse prostacyclin receptors. Identification of critical species-dependent differences. J Biol Chem 277 (2002) 27053-27064
25. Chu K.M., Chow K.B., Wong Y.H., and Wise H. Prostacyclin receptor-mediated activation of extracellular signal-regulated kinases 1 and 2. Cell Sign 16 (2004) 477-486
26. Kam Y., Chow K.B., and Wise H. Factors affecting prostacyclin receptor agonist efficacy in different cell types. Cell Sign 13 (2001) 841-847
27. Mendoza M.C., and Blenis J. PHLPPing it off: phosphatases get in the Akt. Mol Cell 25 (2007) 798-800
28. Gao T., Furnari F., and Newton A.C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18 (2005) 13-24
29. Brognard J., Sierecki E., Gao T., and Newton A.C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25 (2007) 917-931
30. English J., Pearson G., Wilsbacher J., Swantek J., Karandikar M., Xu S., et al. New insights into the control of MAP kinase pathways. Exp Cell Res 253 (1999) 255-270
31. Goldsmith Z.G., and Dhanasekaran D.N. G protein regulation of MAPK networks. Oncogene 26 (2007) 3122-3142
32. DeFea K.A., Zalevsky J., Thoma M.S., Dery O., Mullins R.D., and Bunnett N.W. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 148 (2000) 1267-1281
33. Arehart E., Stitham J., Asselbergs F.W., Douville K., MacKenzie T., Fetalvero K.M., et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 102 (2008) 986-993
34. Patrignani P., Di Febbo C., Tacconelli S., Douville K., Guglielmi M.D., Horvath R.J., et al. Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. Pharmacogenet Genomics 18 (2008) 611-620